Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PhRMA Says Changes To Communications Strategy “Un-Merritted”

Executive Summary

The Pharmaceutical Research & Manufacturers of America plans to continue the "strategic communications" initiative it began last year despite the departure of the team put in place to implement it

You may also be interested in...



PhRMA Public Relations Changes Continue; Bello Overseeing Communications

The Pharmaceutical Research & Manufacturers of America's communications staff will be overseen by Judy Bello during the search for a new VP

PhRMA Public Relations Changes Continue; Bello Overseeing Communications

The Pharmaceutical Research & Manufacturers of America's communications staff will be overseen by Judy Bello during the search for a new VP

Aetna Sees Rx Spending Growing 5%, Premiums At 13%

Aetna sees pharmaceutical spending growing at about one-quarter the peak rate 18 months ago

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS041498

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel